LPH-5 (drug)

LPH-5 (drug)
Clinical data
Drug class	Serotonergic psychedelic; Hallucinogen; Antidepressant; Selective 5-HT2A receptor agonist
ATC code	None;
Legal status
Legal status	In General Unscheduled;
Identifiers
	IUPAC name (S)-3-(2,5-Dimethoxy-4-(trifluoromethyl)phenyl)piperidine;
CAS Number	2641630-97-7 ;
PubChem CID	156337168;
Chemical and physical data
Formula	C14H18F3NO2
Molar mass	289.298 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COC1=CC([C@@]2([H])CNCCC2)=C(OC)C=C1C(F)(F)F;
	InChI InChI=InChI=1S/C14H18F3NO2/c1-19-12-7-11(14(15,16)17)13(20-2)6-10(12)9-4-3-5-18-8-9/h6-7,9,18H,3-5,8H2,1-2H3/t9-/m1/s1; Key:NZKYTYHIERLZBG-SECBINFHSA-N;

LPH-5 is a psychedelic discovered by Emil Marcher-Rørsted, Jesper L. Kristensen and Anders A. Jensen at Danish biopharmaceutical company Lophora. It is a conformationally-restricted derivative of the phenethylamine 2C-TFM, also a hallucinogen, and acts as a potent agonist of the 5-HT_2A receptor (EC₅₀ = 3.2 nM, E_max = 78%). It shows 10- to 100-fold selectivity for the 5-HT_2A receptor over the 5-HT_2B and 5-HT_2C receptors and, along with related compounds like 25CN-NBOH, is said to be one of the few truly selective 5-HT_2A receptor agonists. LPH-5 is expected to avoid the cardiac risks of 5-HT_2B receptor activation.

LPH-48, an analogue of LPH-5 that likewise acts as a selective serotonin 5-HT_2A receptor agonist and psychedelic hallucinogen and shows similar characteristics but has a shorter duration of action, is also under development by Lophora.